Leap Therapeutics, Inc. (LPTX)

Leap Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0	0	1.5	1.5	0
Gross Profit	0	0	1.5	1.5	0
Selling, General & Admin	13.81	11.8	10.77	9.62	9.09
Research & Development	73.23	44.97	32.16	20.42	24.37
Operating Expenses	87.04	56.76	42.93	30.04	33.45
Operating Income	-87.04	-56.76	-41.43	-28.54	-33.45
Interest Expense / Income	0	0.05	0.04	0.04	0.02
Other Expense / Income	-5.63	-2.37	-0.86	-1.06	-0.57
Pretax Income	-81.41	-54.45	-40.61	-27.52	-32.9
Income Tax	0	0.15	-0.02	-0	-0
Net Income	-81.41	-54.6	-40.59	-27.51	-32.9
Preferred Dividends	0	0	0	10.07	0.36
Net Income Common	-81.41	-54.6	-40.59	-37.59	-33.26
Shares Outstanding (Basic)	20	11	9	6	2
Shares Outstanding (Diluted)	20	11	9	6	2
Shares Change	80.55%	31.94%	44.66%	162.71%	56.69%
EPS (Basic)	-3.98	-4.82	-4.70	-6.30	-14.70
EPS (Diluted)	-3.98	-4.82	-4.70	-6.30	-14.70
Free Cash Flow	-43.75	-49.04	-35.16	-25.93	-26.99
Free Cash Flow Per Share	-2.14	-4.33	-4.10	-4.37	-11.95
Gross Margin	-	-	100.00%	100.00%	-
Operating Margin	-	-	-2761.73%	-1902.60%	-
Profit Margin	-	-	-2705.80%	-2505.87%	-
Free Cash Flow Margin	-	-	-2343.80%	-1728.80%	-
EBITDA	-81.4	-54.38	-40.54	-27.44	-32.83
EBITDA Margin	-	-	-2702.73%	-1829.53%	-
Depreciation & Amortization	0.02	0.02	0.03	0.03	0.05
EBIT	-81.41	-54.4	-40.57	-27.48	-32.88
EBIT Margin	-	-	-2704.67%	-1831.80%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).